The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials.
The purpose of this study is to compare abdominal weight gain and fat distribution to changes in brain morphology in people taking antipsychotic medications.
CFDI STUDY with ENZYME REPLACEMENT THERAPY (ERT)
Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60.
Parkinson's Disease (PD) is a progressive neurodegenerative disorder without a cure. While the search for a cure continues, there is a growing interest in psychiological approaches to manage distress in PD. The main objective of this study is to investigate various clinical outcomes in PD associated with different coping styles. Findings from this study will form the basis for projects aimed at designing interventions to foster beneficial coping styles and studies into the neural underpinnings of coping.
This trial will compare a novel form of rTMS, intermittent Theta Burst Stimulation to the standard conventional high frequency left sided stimulation protocol. The Left dorsolateral prefrontal cortex will be the site of stimulation in both treatment conditions. The site of stimulation will be targeted using MRI co-registration.
The objectives of this 15-day study are:
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) who are selected for endovascular revascularization.
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.
There is a new theory that Parkinson's disease may start in the gut, but research is limited. The purpose of this study is to better understand the association between Parkinson's disease and the bacteria and fungi living in the gut and nose.
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment
MS is a disabling neurological disease with a highly variable clinical course including acute disability (relapses when symptoms appear or worsen) and disease progression (steady accumulation of disability in the absence of relapses). There is currently no approved treatment for progressive MS. A principal pathology of MS is the destruction of myelin, which surrounds nerves to speed up signal conduction. We have developed a magnetic resonance imaging technique that provides quantitative measurements of myelin.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.
The Wellness Monitoring for Major Depressive Disorder (MDD) study is a prospective, longitudinal, observational study aimed at identifying biomarkers of relapse in MDD. Results may help refine clinical approach to relapse management, and may ultimately help MDD patients sustain wellness while on antidepressant medication.
This is an exploratory biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-Cell biology in relapsing multiple sclerosis (RMS).
The purpose of this study is to investigate whether a comprehensive group education combined with a lifestyle "activation" program that includes (a) sleep hygiene course, (b) physical activity promotion, and (c) bright light therapy, can improve both sleep quality and cognitive function among 96 community-dwelling older adults.
This study investigates the use of eye tracking technology as a diagnostic tool for mild traumatic brain injury (mTBI) and concussion. We are looking at the effect of additional working memory (short-term memory) load on the smoothness of eye movements in both concussed and healthy populations.
The purpose of this study is to assess the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive (does not enter the body) technique in improving depressive symptoms.
Repetitive transcranial magnetic stimulation (rTMS) is an emerging treatment for medically refractory major depressive disorder (MDD). rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. Dozens of studies and several meta-analyses over the last 15 years have shown that rTMS of the dorsolateral prefrontal cortex (DLPFC) produces statistically significant improvements in MDD, even when medications have failed. However, other possible targets may also yield improvement in symptoms.
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in April 2013, the NBS has been used in over 300 procedures conducted at approximately 20 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 12 months to evaluate procedural success, local control failure rate, and QoL in up to 1,000 patients and up to 50 sites.